Marziye Eshghi, MGH Institute of Health Professions This project will leverage AI-driven analysis of remotely collected speech data to detect early signs of Alzheimer’s disease (AD) by linking speech acoustic and kinematic features to AD molecular pathologies.
Felipe A. Jain, Massachusetts General Hospital, Finale Doshi-Velez, Harvard University. Family caregivers of people living with dementia have high needs for skills training and methods to reduce stress. This project will study the feasibility of a just-in-time adaptive intervention delivered by smartphone to increase engagement and helpfulness of caregiver skills and relaxation content for caregivers.
Tim K. Mackey, S-3 Research LLC, Joshua Yang, California State University, Fullerton. This project will aim to develop TrialChat, an AI-powered chatbot and clinical trial navigator designed to increase participation in Alzheimer’s disease and related dementias (ADRD) clinical trials by providing tailored education, personalized trial matching, and recruitment support for older adults and caregivers.
Raeanne C Moore, UCSD, Yeonsu Song, UCLA. This project will develop and pilot machine learning algorithms to passively monitor cognitive fluctuations among family caregivers of persons living with dementia by analyzing their smartphone typing patterns and speech.
Rhoda Au, Boston University, Laura McIntosh, EmPowerYu. This project will use in-home multimodal sensors to detect changes in daily life activity patterns that indicate fluctuations in cognitive status.
Jeremy Linsley, Operant BioPharma This project will use a proprietary robotics and artificial intelligence to identify targets and clinically-tested drugs that could be repurposed for Alzheimer's disease by blocking the harmful interaction between Tau and Amyloid Precursor proteins.
Chaitanya Gupta, ProbiusDX Inc., Steven Arnold, Massachusetts General Hospital. This project will use Probius QES, a novel technology that measure molecular vibrations in blood plasma samples, to identify and differentiate healthy aging vs Alzheimer’s Disease progression in a well characterized cohort of 1000+ individuals from MassGen.